Actifolic RU-58841 powder and GhK-Cu peptide were tested and found to be accurate. The user is satisfied with the product's authenticity for hair loss treatment.
The user reported significant hair regrowth after one month using Cécred edge drops, microneedling, and finasteride, despite skepticism from others. They had previously tried minoxidil, finasteride, PRP, and other treatments with limited success.
The user is experimenting with a zinc sulfate and B6 topical solution called "Zix" for hair loss, alongside using a zinc oxide scalp mask and low-level laser therapy (LLLT). They report minimal hair loss after three months of use and are seeking feedback from others who have tried similar treatments.
The user plans to switch from finasteride to dutasteride for hair loss and is treating seborrheic dermatitis with Nizoral and Stanhome Balance shampoos. They are considering trying Vichy Psolution shampoo and Ciclopirox, and are dealing with challenges due to Vietnam's humidity.
GHK-RU58841 is used for hair loss, with positive results when combined with finasteride, stemoxydine, redensyl, and alfatradiol. Users report effectiveness after adding finasteride.
A 36-year-old shared a 5-month update on their hair transplant of 3153 grafts, expressing satisfaction with the progress while using finasteride and minoxidil for over 13 years. The user noted uneven growth between the right and left sides and sought advice on whether this is typical at this stage.
A phase 3 trial for Breezula (clascoterone solution) to treat male pattern hair loss has been listed, with 726 participants and a completion date of January 2025. Other treatments mentioned include Aneira Pharma's combination of minoxidil and latanoprost, Triple Hair's combination of minoxidil, latanoprost, and finasteride, and a new microneedling and LLLT device called StimuSIL.
The user used finasteride but stopped due to side effects, then used topical minoxidil for 13 months, and later added KX826/pyrilutamide for 8 months. They experienced shedding after starting pyrilutamide and use minoxidil and KX826 once daily.
Clascoterone 5% solution showed a 539% improvement in hair count compared to placebo, but the actual increase in hair growth is minimal. Users express skepticism about the effectiveness of hair loss treatments.
Copper peptides, specifically GHK-Cu, are discussed as a potential addition to hair loss treatments, possibly working synergistically with Minoxidil to convert vellus hair into terminal hair. The effectiveness and credibility of copper peptides are questioned due to the lack of widespread discussion and potential conflict of interest from the product's creator.
Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.
Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.
Hair mesotherapy with dutasteride is popular in Europe and can be effective, especially when combined with oral dutasteride. Some users suggest using topical dutasteride with microneedling as an alternative, though it may be painful.
The post discusses a user's successful hair regrowth using finasteride, dutasteride, topical minoxidil, and estrogen over nine months. The user, who is male-to-female (mtf), reports significant regrowth and no side effects beyond typical hormone replacement therapy effects.
A US federal judge ruled that using patients' stem cells for medical treatments is not under FDA jurisdiction, potentially speeding up development of stem cell-based hair loss therapies. Some users are optimistic about increased research and development, while others express skepticism about the ruling's impact on safety and efficacy standards.
The conversation discusses the importance of Finasteride for hair loss treatment in the EU and encourages individuals to voice their support to the EMA. It highlights the potential influence of public input on regulatory decisions.
A user is using topical dutasteride, topical finasteride, and minoxidil to address a receding hairline and is seeking opinions on their routine. They report seeing vellus hair growth after nearly three months of use.
A 28-year-old male is experiencing hair loss despite using topical and oral Minoxidil, oral Finasteride, and recently switching to oral Dutasteride. He is considering whether to return to topical Dutasteride or add Dutasteride mesotherapy to better target scalp DHT.
Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.
The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.
The user is documenting their experience with oral dutasteride (dut) 0.5 mg and minoxidil (min) 5 mg for hair loss, planning to add RU58841 after three months. They previously used finasteride with success and are now experiencing increased shedding but also new hair growth.
The user's hair appears to have improved, looking thicker and healthier, especially around the temples, after using topical minoxidil, finasteride, dutasteride, and tretinoin. Most participants agree the last picture shows significant improvement, though one disagrees.
The conversation is about a user's progress with an oral treatment for hair loss using a stack of finasteride, minoxidil, and biotin over two months, noting stabilization after an initial shed. The user mentions using Hims Chews, which are effective but costly, and another user comments that biotin is ineffective.
Peptides, specifically GHK-Cu, are being considered for hair growth benefits, such as increasing blood flow to the scalp and preventing hair follicle shrinkage. A user reported starting GHK-Cu after hearing it made a friend's hair thicker.
The conversation discusses a community called PHG, which focuses on experimental hair loss treatments and scientific approaches to hair regrowth. It mentions treatments like Minoxidil, finasteride, and RU58841, and highlights interest in new treatments like Setipripant, Histogen, and Replicel.
The user shared their 9-month progress using topical finasteride and minoxidil, a Capillus laser cap, and a dermastamp for hair loss. They noted improvements and emphasized the importance of consistency for better results.
User shared 9-month hair regrowth progress using a Fin/Min spray from HIMS, with additional microneedling. Other users praised the results and discussed the effectiveness of topical treatments.
A new treatment using dermal sheath cup cells may regrow hair and could require repeat treatments every 8 years. Users discuss ongoing trials and plan to use finasteride and minoxidil until the treatment is available.
The conversation discusses skepticism about group buys for hair loss treatments, highlighting issues with unverified chemicals and the risks involved. It suggests stabilizing with dutasteride and minoxidil, and considering a hair transplant instead of experimenting with untested products.
The user has been using Minoxidil, Finasteride, and HRT for hair regrowth, but is not fully satisfied with the progress after 11 months. They are considering changing treatments, including possibly switching to Dutasteride and adjusting their HRT regimen.